芪莲舒痞颗粒影响端粒酶活性、端粒长度、DNA含量及NF-κB表达的实验研究
|
摘要
目的：通过研究芪莲舒痞颗粒对CAG癌前病变大鼠胃黏膜组织端粒酶活性、端粒长度、DNA含量及NF-κB表达的影响,探讨芪莲舒痞颗粒逆转CAG癌前病变的作用机理。
方法：采用‘'MNNG+雷尼替丁+乙醇+饥饱失调”的综合方法复制Wistar大鼠CAG癌前病变模型,按体重随机分为正常组、模型组、芪莲舒痞大、中、小剂量组和胃复春阳性对照组,分别给予药物干预后观察：免疫组化、TRAP-ELISA法检测端粒酶活性、端粒长度及NF-κB的表达,用流式细胞仪检测DNA含量。
结果：①胃黏膜病理变化：造模各组大鼠胃黏膜炎症、萎缩、肠上皮化生、异型增生发生例数与正常组比较,均显著增加(P<0.01或P<0.05)；与模型组相比,QLSP大、中剂量组胃黏膜炎症发生例数均显著减少(P<0.01或P<0.05), QLSP大剂量组萎缩、肠上皮化生的发生例数显著减少(P<0.05)；药物干预各组间异型增生的发生例数无统计学差异。②胃黏膜端粒长度：正常组为20.01±1.40bp,模型组13.32±1.62bp,胃复春组16.91±1.88bp,QLSP大、中、小剂量组分别为19.27±1.94bp、17.91±1.63bp、16.23±2.16bp。经统计学分析,模型组、胃复春组、QLSP中、小剂量组端粒长度较正常组明显缩短(P<0.01)；经胃复春、QLSP治疗后,端粒长度较模型组均明显增长(P<0.01)。与胃复春组比较,QLSP大剂量组端粒长度显著增长(P<0.01),QLSP中、小剂量组则无明显差异。③胃黏膜端粒酶活性比较：正常组端粒酶阳性率为0(0/20),模型组为66.7%(10/15),胃复春组为33.3%(5/15),QLSP大、中、小剂量组分别为0(0/15)、26.7%(4/15)、33.3%(5/15)。经统计学分析,模型组、胃复春组、QLSP中小剂量组端粒酶活性与正常组比较明显增强(P<0.01或P<0.05)；QLSP大剂量组端粒酶活性较模型组明显降低,差异有统计学意义(P<0.05)。QLSP中剂量组端粒酶阳性率较胃复春组下降,但无统计学差异。④DNA含量比较：正常组为11.49±2.65μg,模型组36.48±4.81μg,胃复春组26.39±5.85μg,QLSP大、中、小剂量组分别为16.99±4.62μg、20.37±4.70μg、28.41±4.53μg。经统计学分析,模型组、胃复春组、QLSP大、中、小剂量组DNA含量较正常组明显增加(P<0.01)；经胃复春、QLSP治疗后,DNA含量较模型组明显减少(P<0.01)。与胃复春组比较,QLSP大、中剂量组DNA含量显著减少(P<0.01),QLSP小剂量组则无明显差异。⑤胃黏膜NF-κB的表达：正常组阳性表达率为0(0/20),模型组为80%(12/15),胃复春组为33.3%(5/15),QLSP大、中、小剂量组分别为26.7%(4/15)、40%(6/15)、60%(9/15)。经统计学分析,模型组、胃复春组、QLSP大、中、小剂量组胃黏膜NF-KB表达阳性表达率较正常组显著升高(P<0.01或P<0.05)；胃复春组和QLSP大剂量组胃黏膜NF-κB表达阳性表达率较模型组显著下降(P<0.01或P<0.05)；胃复春组、QLSP各剂量组胃黏膜NF-KB表达阳性表达率未见明显差异。
结论：实验结果表明芪莲舒痞方能有效逆转CAG癌前病变,从而证明运脾益肾、化瘀解毒是治疗CAG癌前病变的有效方法。芪莲舒痞颗粒的作用机理可能与其抑制CAG癌前病变大鼠胃黏膜组织端粒长度的缩短,抑制端粒酶的活性及DNA含量的增加,降低DNA多倍体的比例,抑制NF-κB的表达等有关。芪莲舒痞颗粒可能从多个环节、多个靶点阻断和逆转胃黏膜癌前病变。
Objective:To probe into the pharmacodynamic mechanism of Qilian Shupi granule by way of researching on its effecting the activity of telomerase, length of telomere and content of DNA, expression of NF-κB in Wistar rats.
Methods:In experiments, models of precancerous lesions of gastric cancer were induced by cancerogenic agent in Wistar rats, which were divided randomly into six groups (normal group, model group, WeiFuchun group and big, middle and small dose QLSP group) according to their weights. After treated with QLSP and WeiFuchun for 12 weeks, main outcome measures:optical microscope was used to observe gastric mucous membrane; Immunohistochemical methods and TRAP-ELISA were used to monitor the expressions of activity of telomerase、length of telomere and expressions of NF-κB, the content of DNA was detected by FCM.
Results:Animal experimental research showed that the happened number of gastric mucosal inflammation and atrophy, intestinal metaplasia, hyperplasia of gastric mucous membrane in built models groups was more than normal group, there were notable difference between them (P<0.01 or P<0.05); the length of telomere were increased in big and middle doses QLSP group, while they were increased slightly in Wei Fuchun group and lower greatly in model group, there were notable differences among them(P<0.01); The activity of telomerase were decreased in big and middle doses QLSP group, while they were decreased slightly in Wei Fuchun group and higher greatly in model group, there were notable differences among them(P<0.01). The content of DNA was decreased in big and middle doses QLSP group, while they were higher greatly in model group and decreased slightly in Wei Fuchun group, there were notable differences among them(P< 0.01). The expressions of NF-κB was inhibited in big doses QLSP group, while they were increased greatly in model group and inhibited slightly in Wei Fuchun group, there were notable differences among them (P<0.01).
Conclusions:Splenogastric asthenia, accumulation of stagnant pathogenic factors in the body, and involvement of the kidney functions at the advanced stage are the main causes leading to the pathogenesis of precancerous lesions of chronic atrophic gastritis. Therefore, invigorating spleen and tonifying kidney, regulating qi to disperse stagnation, and dispersing accumulation of pathogenic factors to resolve masses are the principles in the management of the condition. The index from experimental research reveals its mechanism at the systemic, cellular and molecular levels in treating precancerous lesions of chronic atrophic gastritis. The QLSP recipe acts on many chains and targets of the disease to produce a comprehensive therapeutic effect, the therapeutic mechanism may have much to do with an overall effect of inhibition of expression of the activity of telomerase、length of telomere and content of DNA、expression of NF-κB. And thus the study enriched the knowledge of pathology and treatment of precancerous lesions of chronic atrophic gastritis.
方法：采用‘'MNNG+雷尼替丁+乙醇+饥饱失调”的综合方法复制Wistar大鼠CAG癌前病变模型,按体重随机分为正常组、模型组、芪莲舒痞大、中、小剂量组和胃复春阳性对照组,分别给予药物干预后观察：免疫组化、TRAP-ELISA法检测端粒酶活性、端粒长度及NF-κB的表达,用流式细胞仪检测DNA含量。
结果：①胃黏膜病理变化：造模各组大鼠胃黏膜炎症、萎缩、肠上皮化生、异型增生发生例数与正常组比较,均显著增加(P<0.01或P<0.05)；与模型组相比,QLSP大、中剂量组胃黏膜炎症发生例数均显著减少(P<0.01或P<0.05), QLSP大剂量组萎缩、肠上皮化生的发生例数显著减少(P<0.05)；药物干预各组间异型增生的发生例数无统计学差异。②胃黏膜端粒长度：正常组为20.01±1.40bp,模型组13.32±1.62bp,胃复春组16.91±1.88bp,QLSP大、中、小剂量组分别为19.27±1.94bp、17.91±1.63bp、16.23±2.16bp。经统计学分析,模型组、胃复春组、QLSP中、小剂量组端粒长度较正常组明显缩短(P<0.01)；经胃复春、QLSP治疗后,端粒长度较模型组均明显增长(P<0.01)。与胃复春组比较,QLSP大剂量组端粒长度显著增长(P<0.01),QLSP中、小剂量组则无明显差异。③胃黏膜端粒酶活性比较：正常组端粒酶阳性率为0(0/20),模型组为66.7%(10/15),胃复春组为33.3%(5/15),QLSP大、中、小剂量组分别为0(0/15)、26.7%(4/15)、33.3%(5/15)。经统计学分析,模型组、胃复春组、QLSP中小剂量组端粒酶活性与正常组比较明显增强(P<0.01或P<0.05)；QLSP大剂量组端粒酶活性较模型组明显降低,差异有统计学意义(P<0.05)。QLSP中剂量组端粒酶阳性率较胃复春组下降,但无统计学差异。④DNA含量比较：正常组为11.49±2.65μg,模型组36.48±4.81μg,胃复春组26.39±5.85μg,QLSP大、中、小剂量组分别为16.99±4.62μg、20.37±4.70μg、28.41±4.53μg。经统计学分析,模型组、胃复春组、QLSP大、中、小剂量组DNA含量较正常组明显增加(P<0.01)；经胃复春、QLSP治疗后,DNA含量较模型组明显减少(P<0.01)。与胃复春组比较,QLSP大、中剂量组DNA含量显著减少(P<0.01),QLSP小剂量组则无明显差异。⑤胃黏膜NF-κB的表达：正常组阳性表达率为0(0/20),模型组为80%(12/15),胃复春组为33.3%(5/15),QLSP大、中、小剂量组分别为26.7%(4/15)、40%(6/15)、60%(9/15)。经统计学分析,模型组、胃复春组、QLSP大、中、小剂量组胃黏膜NF-KB表达阳性表达率较正常组显著升高(P<0.01或P<0.05)；胃复春组和QLSP大剂量组胃黏膜NF-κB表达阳性表达率较模型组显著下降(P<0.01或P<0.05)；胃复春组、QLSP各剂量组胃黏膜NF-KB表达阳性表达率未见明显差异。
结论：实验结果表明芪莲舒痞方能有效逆转CAG癌前病变,从而证明运脾益肾、化瘀解毒是治疗CAG癌前病变的有效方法。芪莲舒痞颗粒的作用机理可能与其抑制CAG癌前病变大鼠胃黏膜组织端粒长度的缩短,抑制端粒酶的活性及DNA含量的增加,降低DNA多倍体的比例,抑制NF-κB的表达等有关。芪莲舒痞颗粒可能从多个环节、多个靶点阻断和逆转胃黏膜癌前病变。
Objective:To probe into the pharmacodynamic mechanism of Qilian Shupi granule by way of researching on its effecting the activity of telomerase, length of telomere and content of DNA, expression of NF-κB in Wistar rats.
Methods:In experiments, models of precancerous lesions of gastric cancer were induced by cancerogenic agent in Wistar rats, which were divided randomly into six groups (normal group, model group, WeiFuchun group and big, middle and small dose QLSP group) according to their weights. After treated with QLSP and WeiFuchun for 12 weeks, main outcome measures:optical microscope was used to observe gastric mucous membrane; Immunohistochemical methods and TRAP-ELISA were used to monitor the expressions of activity of telomerase、length of telomere and expressions of NF-κB, the content of DNA was detected by FCM.
Results:Animal experimental research showed that the happened number of gastric mucosal inflammation and atrophy, intestinal metaplasia, hyperplasia of gastric mucous membrane in built models groups was more than normal group, there were notable difference between them (P<0.01 or P<0.05); the length of telomere were increased in big and middle doses QLSP group, while they were increased slightly in Wei Fuchun group and lower greatly in model group, there were notable differences among them(P<0.01); The activity of telomerase were decreased in big and middle doses QLSP group, while they were decreased slightly in Wei Fuchun group and higher greatly in model group, there were notable differences among them(P<0.01). The content of DNA was decreased in big and middle doses QLSP group, while they were higher greatly in model group and decreased slightly in Wei Fuchun group, there were notable differences among them(P< 0.01). The expressions of NF-κB was inhibited in big doses QLSP group, while they were increased greatly in model group and inhibited slightly in Wei Fuchun group, there were notable differences among them (P<0.01).
Conclusions:Splenogastric asthenia, accumulation of stagnant pathogenic factors in the body, and involvement of the kidney functions at the advanced stage are the main causes leading to the pathogenesis of precancerous lesions of chronic atrophic gastritis. Therefore, invigorating spleen and tonifying kidney, regulating qi to disperse stagnation, and dispersing accumulation of pathogenic factors to resolve masses are the principles in the management of the condition. The index from experimental research reveals its mechanism at the systemic, cellular and molecular levels in treating precancerous lesions of chronic atrophic gastritis. The QLSP recipe acts on many chains and targets of the disease to produce a comprehensive therapeutic effect, the therapeutic mechanism may have much to do with an overall effect of inhibition of expression of the activity of telomerase、length of telomere and content of DNA、expression of NF-κB. And thus the study enriched the knowledge of pathology and treatment of precancerous lesions of chronic atrophic gastritis.
引文
[1]张荫昌.胃癌癌前病变研究的30年进展[J].中国肿瘤,2001；26(1)：学会脾胃病分会.慢性萎缩性胃炎中医诊疗共识意见(2009,深圳)[C].中国中西医结合消化杂志,2010；18(5)：345-349.
[2]王少明,林才经,杨春波.大鼠胃粘膜癌前病变实验动物模型的建立[J].药学实践杂志,2005；23(5)：271-272.
[3]中华中医药.论胃肠疾病与调畅气机[J].上海中医药杂志,2006；40(3)：20-21.
[4]唐旭东.董建华通降论学术思想整理[J].北京中医药大学学报,1995；18(2)：45-48.
[5]王凤云,唐旭东,姚乃礼.论胃肠疾病与调畅气机[J].上海中医药杂志,2006；(3)：406-407.
[6]柴可夫.活血化瘀法防治慢性萎缩性胃炎辨识[J].中医药学刊,2004；22(3)：389-390.
[7]王爱云,单兆伟.慢性萎缩性胃炎从瘀血论治[J].中国中西医结合脾胃杂志,2000；8(5)：290-291.
[8]李胜.从脾胃论治慢性萎缩性胃炎湿寒证38例[J].中国中西医结合脾胃杂志,2000,8(2)：117.
[9]张杰,章天寿.从“虚”、“毒”、“瘀”论治慢性萎缩性胃炎[J].中国中医基础医学杂志.2005,1(1)：44-45.
[10]李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治[J].四川中医.2004,22(1)：17-18.
[11]张艳君.中医治疗慢性萎缩性胃炎的研究近况[J].河北中医,2007；29(10)：957-958.
[12]Dawe, Physiological, factors, affecting, Salivary, flow rateroalsagar. Clearance and the sensation. of dry mouth in Man. J Dent Res 1987.66:648.
[13]陈德珍,穆睦新,顾宇春,等.脾、肾阴虚证病人唾液溶菌酶和唾液流速测定及分析[J].江苏中医,1996,17(11)：42-43.
[14]雷作汉,段永强,成映霞.慢性萎缩性胃炎中医因机证治谈[J].河南中医,2009；29(6)：566-567.
[15]WATANABC T, TADA M, NAGAIH. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils[J]. Gastroentemlogy.1998; 115(3):642-648.
[16]UEMURA N,OKAMOTO S, YAMAMOTO S, et al. Helicobacter pylori infection and the development of gastric cancer[J].N Engl J Med,2001; 345 (11):784-789.
[17]YOSHIDA S, SAITO D.Gastric primalignancy and cancer screening in high-risk patients[J]. Am J Gastroenterol,1996;91:839-843.
[18]SHEU BS, YANG HB, WANG YL, et al. Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylori eradication in patients with non-ulcer dyspepsia[J]. Dig DisSd,2001;46:2700-2707.
[19]ZHOU L, SUNG JJ, L JN S, et al. A five-year follow up study on the pathological changes of gastric mucosa after H. pylori eradication[J]. Chin Med J.2003;116:11-14.
[20]蒋琪,姚秀平,陈益忠.根除幽门螺杆菌对萎缩性胃炎、肠上皮化生的影响[J].医学临床研究,2006,23(12)：1972-1973.
[21]吕宾,王惠萍,陈明涛,等.根除幽门螺旋杆菌对胃粘膜萎缩和肠化生影响的随访研究[J].中华内科杂志,2004；43(4)：299-301.
[22]International Agency for Research on Cancer, World Health Organization Schistosomes, Liver Flukes and Helicobacter pylor. i IARC working group on the evaluation of carcinogenic risks to human[R]. Monogr Eval Carcinog Risks Hum,1994,61:218-220.
[23]周丽雅,林三仁,丁士刚,等.根除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究[J].中华消化杂志,2005；25(6)：324-327.
[24]Wong BC, Lam SK, Wong WM, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China:a randomized controlled trial[J]. JAMA,2004;291 (11): 187-194.
[25]张义平,张丽娟,侯恒,等.慢性胃炎病变黏膜组织HSP70的表达与幽门螺杆菌感染的相关性研究.临床和实验医学杂志.2009,8(10)：7-8.
[26]王韶华,谢永强,李鹏飞.胃黏膜病变中幽门螺杆菌感染与环氧化酶-2、核转录因子关系的探讨[J].北京医学,2007；29(8)：484～486.
[27]Moss S F, Calam J, Agarwol B, et al. Induction of gastric epithelial apoptosis by Helicobacter pylori[J]. Gut,1996,38(4):498-501.
[28]李伏娥,王俊萍,刘永革,等.幽门螺杆菌感染与慢性萎缩性胃炎的相关性[J].中国现代医学杂志.2007；17(17)：2129-2131.
[29]刘思纯.胆汁反流性胃炎[J].新医学,1998；29(5)：232.
[30]Arroyo AJ, Burns JB, Huyghe WA, et al. Entergastric refluxmimicking gallbladder disease:detection, quantitation and potential significance. Jnucl Med Technol,1999;27:20.
[31]杨鸿,侯家玉.胆汁反流致慢性萎缩性胃炎的实验研究[J].北京中医药大学学报.2001,24(5)：26-29.
[32]刘兰,李菊兰.慢性胆囊炎与萎缩性胃炎相关性分析[J].中国误诊学杂志2008；8(34)：8366-8367.
[33]中国胃食管反流病研究协作组.反流性疾病问卷在胃食管反流病诊断中的价值[J].中华消化杂志,2003；23：651.
[34]张玲霞,张沥,陶梅,等.高渗盐水致大鼠萎缩性胃炎胃黏膜扫描电镜观察[J].中国医师杂志.2005；7(11)：1452-1454.
[35]Lam.9 th Seah Cheng Siangmemorial lecture:Gastric cancer-where are we now?[J]. Ann AcadMed Singapore,1999;28(6):881-889.
[36]鲍萍萍,高立峰,刘大可,等.上海市居民饮食与胃癌关系的病例对照研究[J].中国肿瘤,2003；12(2)：66-70.
[37]Green TJ, Venn BJ, Skeaff CM, et al. Serum Vitamine B12 concentrati-ons and atrophic gastritis in older New Zealanders [J]. Eur J Clin Nutr, 2004;13:113115.
[38]Lucy S,ItoSueli M, Obashinjo,suelyK. N, etal. Lifestyle factors ass-ociated with atrophic gastritis among Helicobacter pylori seropositive Japanese Brazilians in Sao Paulo[J]. Int J Clin oncol,2003;8:362-368.
[39]周晓彬,张健,张超英,等.中国人群生活习惯与胃癌发病关系的Meta分析[J].中国临床康复,2006；12：10-13.
[40]Kneller RW, You WC. Cigarette smoking and other risk factors for progression of precancerous research lesions[J].J Natl Cancer Inst, 1993,85:1038-1049.
[41]罗海霞,周丽青,杨晓莹.某地区胃病流行病学调查分析[J].中国医疗前沿.2008；3(15)：102.
[42]柯莹玲,单兆伟.542例慢性萎缩性胃炎患者中医辩证分型与病因分析.辽宁中医杂志,2006；33(2)：161-162.
[43]Modena JL, Acrani GO, Micas AF, et al. Correlation between Helicobacter pylori infection, gastric diseases and life habits among patients treated at a university hospital in Southeast Brazil[J]. Braz J Infect Dis,2007;11(1):89-95.
[44]娄建石.药理学.第一版,北京：人民卫生出版社,2002；113-114.
[45]赵卫东,张威庆,李颖.幽门螺杆菌感染及年龄变化与慢性萎缩性胃炎的关系[J].山东医药,2003；43(34)：51.
[46]萧树东.幽门螺杆菌：基础与临床国际会议[J].胃肠病学,2003；8(1)：4142.
[47]萧树东.江绍基胃肠病学,第1版,上海：上海科技出版社,2001,368.
[48]林瑶光.叶酸、维甲酸对胃癌前病变、胃癌逆转作用及抑癌机制[J].临床消化病杂志,2001；1：14.
[49]Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia:rationale and promise. Cancer cell,2003;4:431-436.
[50]Hu PJ, Yu J, Zeng ZR, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut,2004; 53:195-200.
[51]Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestional metaplasia:results of a randomized controlled trial, Clin Cancer Res,2006;12:4766-4722.
[52]Folkman, Klaysburm, Angiogenetic factor [J]. Science,1987; 235:442.
[53]赵玉斌,肖颖,李佃贵.解毒化浊和胃方阻断大鼠CAG癌前病变的分子生物学机制[J].疑难病杂志,2008；7(1).
[54]陈海金,王惠吉.大鼠胃黏膜萎缩过程中的组织学变化和p16、Bcl-2、增殖细胞核抗原表达[J].胃肠病学,2008；(1).
[55]Baeuerie PA, Baltimore D. NF-κB; ten years after [J]. Cell,1996;87(1): 13-20.
[56]李国平,吴灵飞,蒲泽锦,等.CagA+幽门螺杆菌胃癌前及癌变中NF-κ B的表达增强[J].世界华人消化杂志,2005：13(17)：2064-2068.
[57]朱祖安NF-κB、COX-2、iNOS在胃癌中的表达意义及NSAIDs抗人胃癌SGC-7901细胞生长机制研究.优秀研究生学位论文.徐州医学院.2006.
[58]何兴祥,王家,吴捷莉,等.胃黏膜癌变过程中端粒长度变化及其与细胞内DNA含量的关系[J].中华消化杂志,2001；21(1)：11-14.
[59]Haber DA. Telomeres, cancer, and immortality. New Engl J Med 1995:332:955-956.
[60]Tong QS, Zheng LD, Chen FM, Zeng FQ, Wang L, Dong JH, Lu GC. Selection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer [J].World J Gastroenterol 2005; 11:634-640.
[61]Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis[J]. Arthritis Res Ther 2005;7:R349-358.
[62]Wrzesien-Kus A, Smolewski P, sobczak-Pluta A, Wierzbowska A, Robak T. The inhibitor of apoptosis protein family and its antagonists in acute leukemias [J]. Apoptosis,2004;9:705-715.
[63]Miyachi K, Sasaki K, Onodera S, Taguchi T, Nagamachi M, Kaneko H, Sunagawa M. Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 2003; 6:217-224.
[64]Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival[J]. World J Gastroenterol 2004; 10:3245-3250.
[65]Tu SP, Jiang xH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong W M, Chan AO, Yuen MF, Lam SK, Kung HF. Wong BC. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer[J]. Cancer Res 2003; 63:7724-7732.
[66]Zangemeister-Wittke U, Simon HU. An IAP in action:the multiple roles of survivin in differentiation, immunity and malignancy[J]. Cell Cycle, 2004; 3:1121-1123.
[67]Cai Z, Bao HY, Un MF. Correlation between survivin mRNA expression and homoharringtonine induced apoptosis of malignant hematopoietic cells[J]. Chin Med J (Engl)2005; 118:548-554.
[68]Sanna MG, da Silva Correia J, Ducrey 0, Lee J, Nomoto K, Schrantz N, Deveraux QL, U levitch RJ. IAP suppression of apoptosis involves distinct mechanisms:the TAK1/JNK1 signaling cascade and caspase inhibition[J]. Mol Cell Biol 2002; 22:1754—1766.
[69]吴江雪,徐本玲,黄文林.血管生成抑制因子的研究进展[J].癌症.2005；24(3)：376-84.
[70]吴国明,李昆林.血管生成抑制因子抗肿瘤作用的研究进展[J].中国处方药.2006；1(46)：46-48.
[71]Keshet E, Ben-Sasson SA. Anticancer drug targets:approaching angiogenesis[J].J Clin Invest,1999; 104(11):1497-1501.
[72]李根霞.血管抑素在肿瘤诊断及治疗方面的研究进展[J].中国肿瘤.2003；12(3)：156-159.
[73]房殿春.胃黏膜癌变分子机制及防治研究[J].解放军医学杂志.2005；9(30)：768-772.
[74]梁增文.胃癌前病变的研究进展[J].广西医学.2005；8(27)：1127-1130.
[75]曹志群,张迎泉.芪莲舒痞颗粒对慢性萎缩性胃炎癌前病变大鼠血管生成因子bEGF的影响[J].中药药理与临床.2005；21(2)：41-43.
[76]曹志群.芪莲舒痞颗粒对慢性萎缩性胃炎癌前病变大鼠微血管密度的影响[J].中华中医药杂志,2005；20(3)：556-558.
[77]曹志群,张维东,孙闵,等.芪莲舒痞颗粒对慢性萎缩性胃炎癌前病变大鼠血管生成因子VEGF的影响[J].光明中医,2008；23(1)：15-17.
[78]王璐林,吴鹏.谈慢性萎缩性胃炎癌前病变的中医治疗[J].新疆中医药,2003；(5)：4.
[79]雷云霞,蔡淦,刘群,等.胃癌前病变中医研究进展[J].实用中医内科杂志,2005；19(3)：204-205.
[80]郑世华.胃癌前病变的中医药研究近况[J].河北中医,2002；24(12)：947-949.
[81]郭喜军,王志坤,王石红,等.中医药治疗胃癌癌前病变的临床及实验研究现状与展望[J].中华实用中西医杂志,2005；18(15)：601-603.
[82]曹志群,于大猛,张维东.芪莲舒痞颗粒逆转萎缩性胃炎癌前病变的临床研究[J].河北中医药学报,2003；18(4)：10-13.
[83]邓鑫,梁健,刘东华等.肿瘤防治研究[J].2008；35(5)：313-316.
[84]梁华平,欣波,王正国,等.黄芪多糖、人参茎叶皂贰对创伤后细胞免疫功能的调节作[J].解放军医学杂志,1996；21(1)：12.
[85]王丽群,等.单味黄芪对免疫功能低免疫功能的影响[J].哈尔滨医科大学学报,1996；30(6)：516-518.
[86]高春燕.复方黄芪煎剂对小鼠体液免疫的调节作用[J].西部医学,2010；22(5)：800-801.
[87]马红,王宝恩,马雪梅.黄芪抑制大鼠肝星状细胞增殖及胶原分泌的研究[J].中国中医药信息杂志,2001；8(4)：35-36.
[88]黄坚,万诚.黄芪注射液治疗老年上消化道出血临床观察[J].中国中医急症,2005,14(7)：650-651.
[89]陈长勋.中药药理学[M].上海：上海科学技术出版社,2006.159.
[90]郭棋,彭天庆,杨英珍,等.黄芪对柯萨奇B3病毒感染培养大鼠心肌细胞Ca2+内流及该病毒RNA复制的影响[J].中国中西医结合杂志,1999；15(8)：483-485.
[91]汪硕.黄芪抗肿瘤作用的实验研究[J].中国现代应用药学杂志,2008；25(8)：686-688.
[92]高麟弟.女贞子治疗口疮[J].中草药,1997；28(4)：252.
[93]孙燕,Hersh H.M,李秀如,等.扶正中药的临床和实验研究Ⅲ、黄芪、女贞子水提剂促进免疫功能的实验研究[J].中华微生物和免疫学杂志,1983；3(4)：211-216.
[94]傅勤,王丽娟,景年才,等.扶正中药黄芪、女贞子水煎剂对小鼠巨噬细胞细胞毒功能的作用[J].中国实验临床免疫学杂志,1998；10(1)：44-46
[95]八木晟.薏苡仁的抗癌消炎活性[J].国外医药·植物药分册,1989；4(2)：75.
[96]张明发,沈雅琴,朱自平,等.薏苡仁镇痛抗炎抗血栓形成作用的研究[J].第三军医大学学报,2000；22(6)：578.
[97]杨生,王英杰,张闻.薏苡仁酯对荷瘤小鼠红细胞免疫功能的影响[J].黑龙江医药,1999；12(6)：343-345.
[98]夏卫军,程罗根,徐建亚,等.莪术对黑色素瘤细胞转移相关能力的影响[J].中药药理与临床,2007；23(2)：45-47.
[99]李林,陆兔林,卞慧敏,等.莪术活血化瘀有效物质研究[N].上海中医药大学学报,2004；18(3)：40-42.
[100]解庆东,赵慧男.黄芪抗肿瘤机制研究与临床应用[J].医药导报,2004；23(7)：484-485.
[101]沈洪,刘增巍,朱萱萱,等.莪术对SGC7910胃癌细胞COX-1、COX-2、VEGF和PGE2表达的影响[J].世界华人消化杂志,2006；14(16)：1548-1553.
[102]梁健,邓鑫,黄仁彬.胃宁方对人胃癌SGC-7910细胞增殖凋亡的影响[J].上海中医药杂志,2006；40(9)：66-68.
[103]梁健,邓鑫,黄仁彬.胃宁方对人胃癌细胞侵袭能力的影响[J].辽宁中医杂志,2006；33(7)：899-900.
[104]肖海涛,李铣.半枝莲化学成分和药理活性研究进展[J].中药研究与信息,2005；7(4)：20-22.
[105]张玉茹,朱晓红,李宏捷.复方半枝莲对大鼠口腔癌前病变细胞增殖的作用[J].中草药,2000；31(9)：692-694.
[106]Zhu F S, Si J M. Regulative effect of traditional Chinese medicine on gene-expression related to precancerous lesion of gastric cancer [J].Chin J Integ Med(中西医结合学报),2005；11(1)：76-80.
[107]Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop[J].Cell,1999;97:503.
[108]Fouladi B, Sabatier L, Milller D, et al.The relationship between spontaneous telomere loss and chromosome instability in a human tumor cell line[J].Neoplasia,2000;2(6):540.
[109]Amioka T, Kitadai Y, Hiyama T, et al. Expression of human telomerase reverse transcriptase mRNA in esophageal cancers and precancerous lesions[J]. Oncol Rep,2004;11(1):51-55.
[110]TaRara H, NanisLi T, Kitamoto M, et al. Telomeras activity in Human Liver tissues:Comparision between chronic Liver disease and hepatocellular carcinomas. Cancer Res,1995;55(7):2734.
[111]Wu KJ, Grandori C, Amacker M. Direct activiation of TERT transcription by c-myc[J]. Nature Genel,1999;21(2):220.
[112]Jennifer V, Grobelny, Michelle Kulp-McEliece, et al. Effects of reconstitution of telomerase activity on telomere maintenance by alternative lengthening of telomere(ALT) pathway [J].Hum Mol Genet, 2001:10(18):1953.
[113]Barbara A, Kosciolek T, Kalantidis K, et al. Inhibition of Telomerase Activity in Human Cancer cells by RNA Interference [J]. Mol. Cancer Ther, 2003;2(3):209-215.
[114]Robert F. The significance of telomerase activation and cellular immortalization in human cancer [J]. Mutagenesis,2002;17 (6):539-550.
[115]Wong SC, Yu H, So JB. Detection of telomerase activity in gastric lavage fluid:a novel method to detect gastric cancer[J].J Surg Res,2006; 131(2):252-255.
[116]Nowak J, Januszkiewicz D, Lewandowski K, et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients[J]. Eur J Gastroenterol Hepatol,2003;15(1):75-80.
[117]杨仕明,房殿春,罗元辉,等.胃癌及癌前组织中端粒酶活性的检测及临床意义[J].中华医学杂志,1998；78(3)：207.
[118]谢晶日,王海强,张杨,等.益气养阴利湿活血法对胃癌前病变干预的研究[J].湖北中医,2007；14(21)：63-65.
[119]Sen R, Baltimore D. MultiPle nuelear faetors interaet with the immunoglobulin enhancer sequenees[J].Cell,1986;46 (5):705-716.
[120]Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system[J]. Annu Rev Immunol,1994;(12):141.
[121]Staneovski I, Baltimore D. NF-κ appaB activation:the IKB kinase revealed[J]. Cell,1997;91(3):299-302.
[122]Ghosh S, May MJ, κ appaB, et al. NF-κ appaB and rel Proteins: evolutionarily conserved mediators of immune responses[J]. Annu Rev Immunol,1998;16:225-260.
[123]Mayo MW, Baldwin AS. The transcription factor NF-kappaB:control of oncogenesis and cancer therapy resistance[J]. Biochim BiophysActa, 2000;1470(2):55
[124]汪岩,康劲松,王心蕊,等.膀胱移行细胞癌的CIC-3和NF-κ B的表达及意义[J].吉林大学学报：医学版,2007；33(1)：135
[125]王立芹,于学文,赵子鸽,等.早期自然流产患者绒毛组织中核转录因子-kappaB的表达[J].西安交通大学学报：医学版,2008；29(3)：311.
[126]Ganster RW, Taylor BS, Shao LF, et al. Complex regulation of human inducible nitric oxide synthase gene transcriptionby Statl and NF-κB[J]. Proc NatlAcad SciUSA,2001;98 (15):8638.
[127]林锐,李晓丽,褚燕君.胃癌组织中诱导型一氧化氮合酶、核转录因子-κ B的表达[J].郑州大学学报(医学版),2009；44(2)：371-373.
[128]李春杰,魏品康,余柏林.消痰散结方干预对胃癌组织核转录因子NF-κ B P65蛋白表达影响的研究[J].中国临床保健杂志,2010；13(1)：62-64.
[129]谭恩光.医学细胞生物学[M].第2版.广州：广东高等教育出版社,2000.215.
[130]夏潮涌.图像分析仪在测定肿瘤细胞DNA含量、倍体中的若干问题.中华病理学杂志,1999；28：307-308.
[131]吴德昌.放射医学[M].北京：军事医学科学出版社,2001：1,234～236,23～49.
[132]廖新波,唐国华,陈昌伟.胃癌细胞DNA含量、AgNOR计数与其生物学特性关系的研究.中国组织化学与细胞化学杂志,1995；4：39-44.
[133]左连富,高国栋,郭建文,等.胃癌前病变细胞DNA倍体的研究.中华肿瘤杂志,1991；13：180-183.
[134]Abdel-Wahab M, Attallah AM, Elshal MF, Eldousoky I, Zalata KR, el-Ghawalby NA, Gad el-Hak N, el-Ebidy G, Ezzat F, Correlation between endoscopy, histopathology, and DNA flow cytometry in patients with gastric dyspepsia. Hepatogastroenterology,1996;43:1313-1320.
[1]孟静岩.慢性萎缩性胃炎[M].北京：中国医药科技出版社,2003：8.
[2]李帆.补气益胃汤治疗慢性萎缩性胃炎的临床疗效观察[J].中国现代医生.2009,47(19) ：15-16.
[3]张健,黄卫国.幽门螺杆菌根治术结合胃炎灵治疗慢性萎缩性胃炎55例临床观察[J].海南医学.2009,20(9)：16—18.
[4]马健,李勇,刘春燕.健脾益胃汤联合抗Hp疗法治疗脾胃虚弱型慢性萎缩性胃炎60例疗效观察[J].实用中西医结合临床.2009,9(3)：31-32.
[5]石爱华.电热针结合四君子汤加味治疗脾胃虚寒型慢性萎缩性胃炎临床观察[J].河北中医2009.31(3)：418-420.
[6]雷春红,林一帆.加味四君子汤三联疗法对慢性萎缩性胃炎的疗效观察[J].沈阳部队医药.2009,22(4)：225-227.
[7]康忠禹.足三里注射配合中药治疗慢性萎缩性胃炎35例[J].现代中医药.2009.29(3) ：70-71.
[8]陈宇基.益脾活血消痞汤合黄芪注射液穴注治疗慢性萎缩性胃炎38例[J].新中医.2009,41(2)：70—71.
[9]王光尚.中药内服结合外敷治疗慢性萎缩性胃炎30例[J].中医外治杂志.2009,18(1)：26—27.
[10]陈旋,蔡淦.膏方调治脾虚肝乘型慢性萎缩性胃炎临床观察[J].上海中医药杂志.2010,44(1)：34-35.
[11]刘阳川,张谨,张涛等.珍珠养胃膏治疗慢性萎缩性胃炎100例[J].中国中西医结合消化杂志.2009,17(5)：334—335.
[12]戴剑华,赵建群,易恒.益胃欣免煎剂治疗慢性萎缩性胃炎60例临床观察[J].河北中医.2009,31(6)：856-857.
[13]廖中昶.阿胶联合胃复春治疗慢性萎缩性胃炎临床效果观察[J].实用医院临床杂志.2009,6(6)：95-96.
[14]谷巍,胡起超.针灸治疗慢性萎缩性胃炎疗效对比观察[J].中国针灸.2009,29(5)：361-364.
[15]陈贵廷,杨思澎.实用中西医结合诊断治疗学[M].北京：中国医药科技出版社,1995：425—433.
[16]陈寿波.胃肠病临床药理学[M].北京：科学出版社.1998：107-124.
[2]王少明,林才经,杨春波.大鼠胃粘膜癌前病变实验动物模型的建立[J].药学实践杂志,2005；23(5)：271-272.
[3]中华中医药.论胃肠疾病与调畅气机[J].上海中医药杂志,2006；40(3)：20-21.
[4]唐旭东.董建华通降论学术思想整理[J].北京中医药大学学报,1995；18(2)：45-48.
[5]王凤云,唐旭东,姚乃礼.论胃肠疾病与调畅气机[J].上海中医药杂志,2006；(3)：406-407.
[6]柴可夫.活血化瘀法防治慢性萎缩性胃炎辨识[J].中医药学刊,2004；22(3)：389-390.
[7]王爱云,单兆伟.慢性萎缩性胃炎从瘀血论治[J].中国中西医结合脾胃杂志,2000；8(5)：290-291.
[8]李胜.从脾胃论治慢性萎缩性胃炎湿寒证38例[J].中国中西医结合脾胃杂志,2000,8(2)：117.
[9]张杰,章天寿.从“虚”、“毒”、“瘀”论治慢性萎缩性胃炎[J].中国中医基础医学杂志.2005,1(1)：44-45.
[10]李佃贵,李海滨,裴林,等.慢性萎缩性胃炎从浊毒论治[J].四川中医.2004,22(1)：17-18.
[11]张艳君.中医治疗慢性萎缩性胃炎的研究近况[J].河北中医,2007；29(10)：957-958.
[12]Dawe, Physiological, factors, affecting, Salivary, flow rateroalsagar. Clearance and the sensation. of dry mouth in Man. J Dent Res 1987.66:648.
[13]陈德珍,穆睦新,顾宇春,等.脾、肾阴虚证病人唾液溶菌酶和唾液流速测定及分析[J].江苏中医,1996,17(11)：42-43.
[14]雷作汉,段永强,成映霞.慢性萎缩性胃炎中医因机证治谈[J].河南中医,2009；29(6)：566-567.
[15]WATANABC T, TADA M, NAGAIH. Helicobacter pylori infection induces gastric cancer in Mongolian gerbils[J]. Gastroentemlogy.1998; 115(3):642-648.
[16]UEMURA N,OKAMOTO S, YAMAMOTO S, et al. Helicobacter pylori infection and the development of gastric cancer[J].N Engl J Med,2001; 345 (11):784-789.
[17]YOSHIDA S, SAITO D.Gastric primalignancy and cancer screening in high-risk patients[J]. Am J Gastroenterol,1996;91:839-843.
[18]SHEU BS, YANG HB, WANG YL, et al. Pretreatment gastric histology is helpful to predict the symptomatic response after H. pylori eradication in patients with non-ulcer dyspepsia[J]. Dig DisSd,2001;46:2700-2707.
[19]ZHOU L, SUNG JJ, L JN S, et al. A five-year follow up study on the pathological changes of gastric mucosa after H. pylori eradication[J]. Chin Med J.2003;116:11-14.
[20]蒋琪,姚秀平,陈益忠.根除幽门螺杆菌对萎缩性胃炎、肠上皮化生的影响[J].医学临床研究,2006,23(12)：1972-1973.
[21]吕宾,王惠萍,陈明涛,等.根除幽门螺旋杆菌对胃粘膜萎缩和肠化生影响的随访研究[J].中华内科杂志,2004；43(4)：299-301.
[22]International Agency for Research on Cancer, World Health Organization Schistosomes, Liver Flukes and Helicobacter pylor. i IARC working group on the evaluation of carcinogenic risks to human[R]. Monogr Eval Carcinog Risks Hum,1994,61:218-220.
[23]周丽雅,林三仁,丁士刚,等.根除幽门螺杆菌对胃癌患病率及胃黏膜组织学变化的八年随访研究[J].中华消化杂志,2005；25(6)：324-327.
[24]Wong BC, Lam SK, Wong WM, et al. China Gastric Cancer Study Group. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China:a randomized controlled trial[J]. JAMA,2004;291 (11): 187-194.
[25]张义平,张丽娟,侯恒,等.慢性胃炎病变黏膜组织HSP70的表达与幽门螺杆菌感染的相关性研究.临床和实验医学杂志.2009,8(10)：7-8.
[26]王韶华,谢永强,李鹏飞.胃黏膜病变中幽门螺杆菌感染与环氧化酶-2、核转录因子关系的探讨[J].北京医学,2007；29(8)：484～486.
[27]Moss S F, Calam J, Agarwol B, et al. Induction of gastric epithelial apoptosis by Helicobacter pylori[J]. Gut,1996,38(4):498-501.
[28]李伏娥,王俊萍,刘永革,等.幽门螺杆菌感染与慢性萎缩性胃炎的相关性[J].中国现代医学杂志.2007；17(17)：2129-2131.
[29]刘思纯.胆汁反流性胃炎[J].新医学,1998；29(5)：232.
[30]Arroyo AJ, Burns JB, Huyghe WA, et al. Entergastric refluxmimicking gallbladder disease:detection, quantitation and potential significance. Jnucl Med Technol,1999;27:20.
[31]杨鸿,侯家玉.胆汁反流致慢性萎缩性胃炎的实验研究[J].北京中医药大学学报.2001,24(5)：26-29.
[32]刘兰,李菊兰.慢性胆囊炎与萎缩性胃炎相关性分析[J].中国误诊学杂志2008；8(34)：8366-8367.
[33]中国胃食管反流病研究协作组.反流性疾病问卷在胃食管反流病诊断中的价值[J].中华消化杂志,2003；23：651.
[34]张玲霞,张沥,陶梅,等.高渗盐水致大鼠萎缩性胃炎胃黏膜扫描电镜观察[J].中国医师杂志.2005；7(11)：1452-1454.
[35]Lam.9 th Seah Cheng Siangmemorial lecture:Gastric cancer-where are we now?[J]. Ann AcadMed Singapore,1999;28(6):881-889.
[36]鲍萍萍,高立峰,刘大可,等.上海市居民饮食与胃癌关系的病例对照研究[J].中国肿瘤,2003；12(2)：66-70.
[37]Green TJ, Venn BJ, Skeaff CM, et al. Serum Vitamine B12 concentrati-ons and atrophic gastritis in older New Zealanders [J]. Eur J Clin Nutr, 2004;13:113115.
[38]Lucy S,ItoSueli M, Obashinjo,suelyK. N, etal. Lifestyle factors ass-ociated with atrophic gastritis among Helicobacter pylori seropositive Japanese Brazilians in Sao Paulo[J]. Int J Clin oncol,2003;8:362-368.
[39]周晓彬,张健,张超英,等.中国人群生活习惯与胃癌发病关系的Meta分析[J].中国临床康复,2006；12：10-13.
[40]Kneller RW, You WC. Cigarette smoking and other risk factors for progression of precancerous research lesions[J].J Natl Cancer Inst, 1993,85:1038-1049.
[41]罗海霞,周丽青,杨晓莹.某地区胃病流行病学调查分析[J].中国医疗前沿.2008；3(15)：102.
[42]柯莹玲,单兆伟.542例慢性萎缩性胃炎患者中医辩证分型与病因分析.辽宁中医杂志,2006；33(2)：161-162.
[43]Modena JL, Acrani GO, Micas AF, et al. Correlation between Helicobacter pylori infection, gastric diseases and life habits among patients treated at a university hospital in Southeast Brazil[J]. Braz J Infect Dis,2007;11(1):89-95.
[44]娄建石.药理学.第一版,北京：人民卫生出版社,2002；113-114.
[45]赵卫东,张威庆,李颖.幽门螺杆菌感染及年龄变化与慢性萎缩性胃炎的关系[J].山东医药,2003；43(34)：51.
[46]萧树东.幽门螺杆菌：基础与临床国际会议[J].胃肠病学,2003；8(1)：4142.
[47]萧树东.江绍基胃肠病学,第1版,上海：上海科技出版社,2001,368.
[48]林瑶光.叶酸、维甲酸对胃癌前病变、胃癌逆转作用及抑癌机制[J].临床消化病杂志,2001；1：14.
[49]Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia:rationale and promise. Cancer cell,2003;4:431-436.
[50]Hu PJ, Yu J, Zeng ZR, et al. Chemoprevention of gastric cancer by celecoxib in rats. Gut,2004; 53:195-200.
[51]Leung WK, Ng EK, Chan FK, et al. Effects of long-term rofecoxib on gastric intestional metaplasia:results of a randomized controlled trial, Clin Cancer Res,2006;12:4766-4722.
[52]Folkman, Klaysburm, Angiogenetic factor [J]. Science,1987; 235:442.
[53]赵玉斌,肖颖,李佃贵.解毒化浊和胃方阻断大鼠CAG癌前病变的分子生物学机制[J].疑难病杂志,2008；7(1).
[54]陈海金,王惠吉.大鼠胃黏膜萎缩过程中的组织学变化和p16、Bcl-2、增殖细胞核抗原表达[J].胃肠病学,2008；(1).
[55]Baeuerie PA, Baltimore D. NF-κB; ten years after [J]. Cell,1996;87(1): 13-20.
[56]李国平,吴灵飞,蒲泽锦,等.CagA+幽门螺杆菌胃癌前及癌变中NF-κ B的表达增强[J].世界华人消化杂志,2005：13(17)：2064-2068.
[57]朱祖安NF-κB、COX-2、iNOS在胃癌中的表达意义及NSAIDs抗人胃癌SGC-7901细胞生长机制研究.优秀研究生学位论文.徐州医学院.2006.
[58]何兴祥,王家,吴捷莉,等.胃黏膜癌变过程中端粒长度变化及其与细胞内DNA含量的关系[J].中华消化杂志,2001；21(1)：11-14.
[59]Haber DA. Telomeres, cancer, and immortality. New Engl J Med 1995:332:955-956.
[60]Tong QS, Zheng LD, Chen FM, Zeng FQ, Wang L, Dong JH, Lu GC. Selection of optimal antisense accessible sites of survivin and its application in treatment of gastric cancer [J].World J Gastroenterol 2005; 11:634-640.
[61]Bokarewa M, Lindblad S, Bokarew D, Tarkowski A. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis[J]. Arthritis Res Ther 2005;7:R349-358.
[62]Wrzesien-Kus A, Smolewski P, sobczak-Pluta A, Wierzbowska A, Robak T. The inhibitor of apoptosis protein family and its antagonists in acute leukemias [J]. Apoptosis,2004;9:705-715.
[63]Miyachi K, Sasaki K, Onodera S, Taguchi T, Nagamachi M, Kaneko H, Sunagawa M. Correlation between survivin mRNA expression and lymph node metastasis in gastric cancer. Gastric Cancer 2003; 6:217-224.
[64]Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival[J]. World J Gastroenterol 2004; 10:3245-3250.
[65]Tu SP, Jiang xH, Lin MC, Cui JT, Yang Y, Lum CT, Zou B, Zhu YB, Jiang SH, Wong W M, Chan AO, Yuen MF, Lam SK, Kung HF. Wong BC. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer[J]. Cancer Res 2003; 63:7724-7732.
[66]Zangemeister-Wittke U, Simon HU. An IAP in action:the multiple roles of survivin in differentiation, immunity and malignancy[J]. Cell Cycle, 2004; 3:1121-1123.
[67]Cai Z, Bao HY, Un MF. Correlation between survivin mRNA expression and homoharringtonine induced apoptosis of malignant hematopoietic cells[J]. Chin Med J (Engl)2005; 118:548-554.
[68]Sanna MG, da Silva Correia J, Ducrey 0, Lee J, Nomoto K, Schrantz N, Deveraux QL, U levitch RJ. IAP suppression of apoptosis involves distinct mechanisms:the TAK1/JNK1 signaling cascade and caspase inhibition[J]. Mol Cell Biol 2002; 22:1754—1766.
[69]吴江雪,徐本玲,黄文林.血管生成抑制因子的研究进展[J].癌症.2005；24(3)：376-84.
[70]吴国明,李昆林.血管生成抑制因子抗肿瘤作用的研究进展[J].中国处方药.2006；1(46)：46-48.
[71]Keshet E, Ben-Sasson SA. Anticancer drug targets:approaching angiogenesis[J].J Clin Invest,1999; 104(11):1497-1501.
[72]李根霞.血管抑素在肿瘤诊断及治疗方面的研究进展[J].中国肿瘤.2003；12(3)：156-159.
[73]房殿春.胃黏膜癌变分子机制及防治研究[J].解放军医学杂志.2005；9(30)：768-772.
[74]梁增文.胃癌前病变的研究进展[J].广西医学.2005；8(27)：1127-1130.
[75]曹志群,张迎泉.芪莲舒痞颗粒对慢性萎缩性胃炎癌前病变大鼠血管生成因子bEGF的影响[J].中药药理与临床.2005；21(2)：41-43.
[76]曹志群.芪莲舒痞颗粒对慢性萎缩性胃炎癌前病变大鼠微血管密度的影响[J].中华中医药杂志,2005；20(3)：556-558.
[77]曹志群,张维东,孙闵,等.芪莲舒痞颗粒对慢性萎缩性胃炎癌前病变大鼠血管生成因子VEGF的影响[J].光明中医,2008；23(1)：15-17.
[78]王璐林,吴鹏.谈慢性萎缩性胃炎癌前病变的中医治疗[J].新疆中医药,2003；(5)：4.
[79]雷云霞,蔡淦,刘群,等.胃癌前病变中医研究进展[J].实用中医内科杂志,2005；19(3)：204-205.
[80]郑世华.胃癌前病变的中医药研究近况[J].河北中医,2002；24(12)：947-949.
[81]郭喜军,王志坤,王石红,等.中医药治疗胃癌癌前病变的临床及实验研究现状与展望[J].中华实用中西医杂志,2005；18(15)：601-603.
[82]曹志群,于大猛,张维东.芪莲舒痞颗粒逆转萎缩性胃炎癌前病变的临床研究[J].河北中医药学报,2003；18(4)：10-13.
[83]邓鑫,梁健,刘东华等.肿瘤防治研究[J].2008；35(5)：313-316.
[84]梁华平,欣波,王正国,等.黄芪多糖、人参茎叶皂贰对创伤后细胞免疫功能的调节作[J].解放军医学杂志,1996；21(1)：12.
[85]王丽群,等.单味黄芪对免疫功能低免疫功能的影响[J].哈尔滨医科大学学报,1996；30(6)：516-518.
[86]高春燕.复方黄芪煎剂对小鼠体液免疫的调节作用[J].西部医学,2010；22(5)：800-801.
[87]马红,王宝恩,马雪梅.黄芪抑制大鼠肝星状细胞增殖及胶原分泌的研究[J].中国中医药信息杂志,2001；8(4)：35-36.
[88]黄坚,万诚.黄芪注射液治疗老年上消化道出血临床观察[J].中国中医急症,2005,14(7)：650-651.
[89]陈长勋.中药药理学[M].上海：上海科学技术出版社,2006.159.
[90]郭棋,彭天庆,杨英珍,等.黄芪对柯萨奇B3病毒感染培养大鼠心肌细胞Ca2+内流及该病毒RNA复制的影响[J].中国中西医结合杂志,1999；15(8)：483-485.
[91]汪硕.黄芪抗肿瘤作用的实验研究[J].中国现代应用药学杂志,2008；25(8)：686-688.
[92]高麟弟.女贞子治疗口疮[J].中草药,1997；28(4)：252.
[93]孙燕,Hersh H.M,李秀如,等.扶正中药的临床和实验研究Ⅲ、黄芪、女贞子水提剂促进免疫功能的实验研究[J].中华微生物和免疫学杂志,1983；3(4)：211-216.
[94]傅勤,王丽娟,景年才,等.扶正中药黄芪、女贞子水煎剂对小鼠巨噬细胞细胞毒功能的作用[J].中国实验临床免疫学杂志,1998；10(1)：44-46
[95]八木晟.薏苡仁的抗癌消炎活性[J].国外医药·植物药分册,1989；4(2)：75.
[96]张明发,沈雅琴,朱自平,等.薏苡仁镇痛抗炎抗血栓形成作用的研究[J].第三军医大学学报,2000；22(6)：578.
[97]杨生,王英杰,张闻.薏苡仁酯对荷瘤小鼠红细胞免疫功能的影响[J].黑龙江医药,1999；12(6)：343-345.
[98]夏卫军,程罗根,徐建亚,等.莪术对黑色素瘤细胞转移相关能力的影响[J].中药药理与临床,2007；23(2)：45-47.
[99]李林,陆兔林,卞慧敏,等.莪术活血化瘀有效物质研究[N].上海中医药大学学报,2004；18(3)：40-42.
[100]解庆东,赵慧男.黄芪抗肿瘤机制研究与临床应用[J].医药导报,2004；23(7)：484-485.
[101]沈洪,刘增巍,朱萱萱,等.莪术对SGC7910胃癌细胞COX-1、COX-2、VEGF和PGE2表达的影响[J].世界华人消化杂志,2006；14(16)：1548-1553.
[102]梁健,邓鑫,黄仁彬.胃宁方对人胃癌SGC-7910细胞增殖凋亡的影响[J].上海中医药杂志,2006；40(9)：66-68.
[103]梁健,邓鑫,黄仁彬.胃宁方对人胃癌细胞侵袭能力的影响[J].辽宁中医杂志,2006；33(7)：899-900.
[104]肖海涛,李铣.半枝莲化学成分和药理活性研究进展[J].中药研究与信息,2005；7(4)：20-22.
[105]张玉茹,朱晓红,李宏捷.复方半枝莲对大鼠口腔癌前病变细胞增殖的作用[J].中草药,2000；31(9)：692-694.
[106]Zhu F S, Si J M. Regulative effect of traditional Chinese medicine on gene-expression related to precancerous lesion of gastric cancer [J].Chin J Integ Med(中西医结合学报),2005；11(1)：76-80.
[107]Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop[J].Cell,1999;97:503.
[108]Fouladi B, Sabatier L, Milller D, et al.The relationship between spontaneous telomere loss and chromosome instability in a human tumor cell line[J].Neoplasia,2000;2(6):540.
[109]Amioka T, Kitadai Y, Hiyama T, et al. Expression of human telomerase reverse transcriptase mRNA in esophageal cancers and precancerous lesions[J]. Oncol Rep,2004;11(1):51-55.
[110]TaRara H, NanisLi T, Kitamoto M, et al. Telomeras activity in Human Liver tissues:Comparision between chronic Liver disease and hepatocellular carcinomas. Cancer Res,1995;55(7):2734.
[111]Wu KJ, Grandori C, Amacker M. Direct activiation of TERT transcription by c-myc[J]. Nature Genel,1999;21(2):220.
[112]Jennifer V, Grobelny, Michelle Kulp-McEliece, et al. Effects of reconstitution of telomerase activity on telomere maintenance by alternative lengthening of telomere(ALT) pathway [J].Hum Mol Genet, 2001:10(18):1953.
[113]Barbara A, Kosciolek T, Kalantidis K, et al. Inhibition of Telomerase Activity in Human Cancer cells by RNA Interference [J]. Mol. Cancer Ther, 2003;2(3):209-215.
[114]Robert F. The significance of telomerase activation and cellular immortalization in human cancer [J]. Mutagenesis,2002;17 (6):539-550.
[115]Wong SC, Yu H, So JB. Detection of telomerase activity in gastric lavage fluid:a novel method to detect gastric cancer[J].J Surg Res,2006; 131(2):252-255.
[116]Nowak J, Januszkiewicz D, Lewandowski K, et al. Activity and expression of human telomerase in normal and malignant cells in gastric and colon cancer patients[J]. Eur J Gastroenterol Hepatol,2003;15(1):75-80.
[117]杨仕明,房殿春,罗元辉,等.胃癌及癌前组织中端粒酶活性的检测及临床意义[J].中华医学杂志,1998；78(3)：207.
[118]谢晶日,王海强,张杨,等.益气养阴利湿活血法对胃癌前病变干预的研究[J].湖北中医,2007；14(21)：63-65.
[119]Sen R, Baltimore D. MultiPle nuelear faetors interaet with the immunoglobulin enhancer sequenees[J].Cell,1986;46 (5):705-716.
[120]Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system[J]. Annu Rev Immunol,1994;(12):141.
[121]Staneovski I, Baltimore D. NF-κ appaB activation:the IKB kinase revealed[J]. Cell,1997;91(3):299-302.
[122]Ghosh S, May MJ, κ appaB, et al. NF-κ appaB and rel Proteins: evolutionarily conserved mediators of immune responses[J]. Annu Rev Immunol,1998;16:225-260.
[123]Mayo MW, Baldwin AS. The transcription factor NF-kappaB:control of oncogenesis and cancer therapy resistance[J]. Biochim BiophysActa, 2000;1470(2):55
[124]汪岩,康劲松,王心蕊,等.膀胱移行细胞癌的CIC-3和NF-κ B的表达及意义[J].吉林大学学报：医学版,2007；33(1)：135
[125]王立芹,于学文,赵子鸽,等.早期自然流产患者绒毛组织中核转录因子-kappaB的表达[J].西安交通大学学报：医学版,2008；29(3)：311.
[126]Ganster RW, Taylor BS, Shao LF, et al. Complex regulation of human inducible nitric oxide synthase gene transcriptionby Statl and NF-κB[J]. Proc NatlAcad SciUSA,2001;98 (15):8638.
[127]林锐,李晓丽,褚燕君.胃癌组织中诱导型一氧化氮合酶、核转录因子-κ B的表达[J].郑州大学学报(医学版),2009；44(2)：371-373.
[128]李春杰,魏品康,余柏林.消痰散结方干预对胃癌组织核转录因子NF-κ B P65蛋白表达影响的研究[J].中国临床保健杂志,2010；13(1)：62-64.
[129]谭恩光.医学细胞生物学[M].第2版.广州：广东高等教育出版社,2000.215.
[130]夏潮涌.图像分析仪在测定肿瘤细胞DNA含量、倍体中的若干问题.中华病理学杂志,1999；28：307-308.
[131]吴德昌.放射医学[M].北京：军事医学科学出版社,2001：1,234～236,23～49.
[132]廖新波,唐国华,陈昌伟.胃癌细胞DNA含量、AgNOR计数与其生物学特性关系的研究.中国组织化学与细胞化学杂志,1995；4：39-44.
[133]左连富,高国栋,郭建文,等.胃癌前病变细胞DNA倍体的研究.中华肿瘤杂志,1991；13：180-183.
[134]Abdel-Wahab M, Attallah AM, Elshal MF, Eldousoky I, Zalata KR, el-Ghawalby NA, Gad el-Hak N, el-Ebidy G, Ezzat F, Correlation between endoscopy, histopathology, and DNA flow cytometry in patients with gastric dyspepsia. Hepatogastroenterology,1996;43:1313-1320.
[1]孟静岩.慢性萎缩性胃炎[M].北京：中国医药科技出版社,2003：8.
[2]李帆.补气益胃汤治疗慢性萎缩性胃炎的临床疗效观察[J].中国现代医生.2009,47(19) ：15-16.
[3]张健,黄卫国.幽门螺杆菌根治术结合胃炎灵治疗慢性萎缩性胃炎55例临床观察[J].海南医学.2009,20(9)：16—18.
[4]马健,李勇,刘春燕.健脾益胃汤联合抗Hp疗法治疗脾胃虚弱型慢性萎缩性胃炎60例疗效观察[J].实用中西医结合临床.2009,9(3)：31-32.
[5]石爱华.电热针结合四君子汤加味治疗脾胃虚寒型慢性萎缩性胃炎临床观察[J].河北中医2009.31(3)：418-420.
[6]雷春红,林一帆.加味四君子汤三联疗法对慢性萎缩性胃炎的疗效观察[J].沈阳部队医药.2009,22(4)：225-227.
[7]康忠禹.足三里注射配合中药治疗慢性萎缩性胃炎35例[J].现代中医药.2009.29(3) ：70-71.
[8]陈宇基.益脾活血消痞汤合黄芪注射液穴注治疗慢性萎缩性胃炎38例[J].新中医.2009,41(2)：70—71.
[9]王光尚.中药内服结合外敷治疗慢性萎缩性胃炎30例[J].中医外治杂志.2009,18(1)：26—27.
[10]陈旋,蔡淦.膏方调治脾虚肝乘型慢性萎缩性胃炎临床观察[J].上海中医药杂志.2010,44(1)：34-35.
[11]刘阳川,张谨,张涛等.珍珠养胃膏治疗慢性萎缩性胃炎100例[J].中国中西医结合消化杂志.2009,17(5)：334—335.
[12]戴剑华,赵建群,易恒.益胃欣免煎剂治疗慢性萎缩性胃炎60例临床观察[J].河北中医.2009,31(6)：856-857.
[13]廖中昶.阿胶联合胃复春治疗慢性萎缩性胃炎临床效果观察[J].实用医院临床杂志.2009,6(6)：95-96.
[14]谷巍,胡起超.针灸治疗慢性萎缩性胃炎疗效对比观察[J].中国针灸.2009,29(5)：361-364.
[15]陈贵廷,杨思澎.实用中西医结合诊断治疗学[M].北京：中国医药科技出版社,1995：425—433.
[16]陈寿波.胃肠病临床药理学[M].北京：科学出版社.1998：107-124.